Breast cancer

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, April 3, 2024
Professional Services, Pharmaceutical, Oncology, Data Management, Consumer, Technology, Artificial Intelligence, Health Technology, Data Analytics, Women, Biotechnology, Health, Helmy Eltoukhy, Patient, Neoplasm, Research, AACR, Epigenomics, Breast cancer, MRD

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.
  • Multiple poster sessions will report on the utility of using the Guardant Infinity™ platform across the continuum of cancer care, ranging from predictive histologic subtyping of tumors to cardiac adverse event prediction.
  • Data will also be presented demonstrating strong performance of Guardant Reveal for minimal residual disease (MRD) detection in breast cancer, allowing quantification of ctDNA even in early-stage disease without the need for a tissue specimen.
  • “We look forward to sharing new data at AACR, in particular studies demonstrating the potential for epigenomic analysis using the Guardant Infinity platform to advance cancer research,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Breast cancer, Goserelin, Patient, Lung, Social media, Immunoglobulin G, National Cancer Institute, Neoplasm, Merck & Co., TNBC, Capecitabine, DXD, BRCA, Clinical Cancer Research, Metabolism, Immunology, Biopharmaceutical, World Health Organization, Cancer, Safety, ADC, BLA, Daiichi Sankyo, Vinorelbine, IHC, Mutation, NSCLC, Disease, Merck, AKT, Death, MD, AstraZeneca, PARP, Oncotarget, PFS, FDA, OS, HER2, Eribulin, Cleavage, Progression-free survival, Triple-negative breast cancer, Female, Emerging, Olaparib, Biology, Sapporo Medical University, Medicine, Pharmaceutical industry

The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.

Key Points: 
  • The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.
  • A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC) and HR-positive, HER2-negative breast cancer.
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, FDA, Clinical Trials, General Health, Pharmaceutical, OS, HER2, IHC, HR, Neutropenia, Congress, DXD, AstraZeneca, NSCLC, Progression-free survival, Patient, Stomatitis, Lung, Doctor of Philosophy, MD, Breast cancer, Anemia, PFS, Fatigue, ADC, Food, BLA, Daiichi Sankyo, PDUFA, Pharmaceutical industry

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.

Key Points: 
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.
  • The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.
  • “The FDA’s acceptance of the BLA brings us closer to providing patients with previously treated HR positive, HER2 negative breast cancer an alternative option to conventional chemotherapy earlier in the metastatic setting,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.

Springer Nature and the Breast Cancer Research Foundation Announce the Rising Scholars: Breast Cancer Program for Early Career Researchers

Retrieved on: 
Tuesday, March 26, 2024
General Health, Oncology, Training, Consumer, Other Education, Continuing, Education, Publishing, Science, Women, Communications, Health, Other Science, Breast cancer, Breast Cancer Research Foundation, University, Master, Disease, Partnership, Breast, Nature Portfolio, Research, Mortality, Nature, Cancer, BCRF, Woman, Workforce, Springer Nature, Disaster recovery, DEI, Writing, Management

Springer Nature and the Breast Cancer Research Foundation (BCRF) today announced the Rising Scholars: Breast Cancer program, a partnership between Nature Portfolio and BCRF which provides Early Career Researchers (ECRs) in the field of cancer with additional resources for professional development and career preparedness.

Key Points: 
  • Springer Nature and the Breast Cancer Research Foundation (BCRF) today announced the Rising Scholars: Breast Cancer program, a partnership between Nature Portfolio and BCRF which provides Early Career Researchers (ECRs) in the field of cancer with additional resources for professional development and career preparedness.
  • The Rising Scholars: Breast Cancer program is the result of over a decade of partnership between Springer Nature and BCRF.
  • BCRF has been a phenomenal and consistent partner for Springer Nature and was the first nonprofit to work with Springer Nature in adopting our data research solutions.
  • The new Rising Scholars: Breast Cancer program will provide concrete qualitative and quantitative data as to the impact of such endeavors going forward.

Lumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual Meeting

Retrieved on: 
Monday, March 25, 2024
Health, Surgery, Oncology, Medical Devices, Breast cancer, Feasibility, Detection, DVS, Massachusetts General Hospital, Light, Inc., Patient, Neoplasm, Stanford University Medical Center, NDA, University, Doctor of Philosophy, Society, Surgeon, Patient satisfaction, Surgical oncology, SSO, Hospital, PMA, Multimedia, MD Anderson Cancer Center, FDA, Associate professor, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240325761901/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240325761901/en/
    Barbara Smith, M.D, PhD., presented results from the INSITE study during the Breast Cancer Hub Zone talk during the SSO Annual Meeting 2024.
  • “It’s so energizing to see such a diversity of surgeons across different specialties come together to advance the collective field of surgical oncology,” said Jorge Ferrer, M.D., PhD, Chief Scientific Officer, Lumicell.
  • Most recently, the FDA’s Medical Imaging Drugs Advisory Committee (MIDAC) voted in support of the benefit-risk profile of LUMISIGHT™ (pegulicianine) during its March 5, 2024 meeting .
  • The FDA is expected to make a decision on Lumicell’s NDA and PMA in the near future.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Monday, March 25, 2024
Technology, Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, Science, Consumer Electronics, Human Genome Project, WGS, Blood pressure, Genomics, Certification, Informatics, Genetic testing, Nucleus, Risk, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1, Vaccine

Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer’s entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the sequencing company’s newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors

Retrieved on: 
Monday, March 25, 2024
Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Clinical Trials, Toxicity, CDK7, Apoptosis, Hebrew University of Jerusalem, CRH, CRi, AML, Patient, Immunology, Acute myeloid leukemia, Cancer, Medicine, Alta Partners, Therapy, Drug development, Breast cancer, Safety, Azacitidine, Pharmacokinetics, CDK9, Bone marrow, Pharmaceutical industry

Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of The Hebrew University of Jerusalem, in 2023 and will use the Series A funding to advance efficacy studies in AML and breast cancer.

Key Points: 
  • Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of The Hebrew University of Jerusalem, in 2023 and will use the Series A funding to advance efficacy studies in AML and breast cancer.
  • “We formed Edgewood Oncology because of the synergistic mechanism of action and promising safety and anti-tumor data that was observed with BTX-A51 in Phase 1 in AML and solid tumor patients.
  • In a Phase 1 study in heavily pre-treated R/R AML patients, monotherapy BTX-A51 demonstrated a favorable safety profile and encouraging antileukemic activity.
  • As a next step, Edgewood initiated a study of BTX-A51 in combination with azacitidine in R/R AML patients in December 2023.

MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

Retrieved on: 
Thursday, March 21, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Lung cancer, Internal medicine, Immunotherapy, Patient, Cancer, Human, Quality of life, Hacettepe University, Breast cancer, Melanoma, SAB, Poster, Multimedia, University of Regensburg

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D.

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D.
  • View the full release here: https://www.businesswire.com/news/home/20240321173734/en/
    Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire)
    Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hospital in Turkey.
  • “He is a prominent voice on medical oncology and cancer epidemiology, with a special interest in quality of life for cancer patients.
  • In the same year, he graduated from the Cancer Epidemiology Master's Program at the Hacettepe University Oncology Institute, Department of Preventive Oncology.

Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, IO, Conference, Entrepreneurship, Response, Immunotherapy, Partnership, Risk, Patient, MammaPrint, University, Biology, University of California, Imprint, Genomics, Breast cancer, Medical laboratory, RPS, Pharmaceutical industry

Agendia®, Inc. today announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.

Key Points: 
  • Agendia®, Inc. today announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.
  • Agendia has been in partnership with Quantum Leap Healthcare Collaborative, the sponsors of the neoadjuvant biomarker-rich I-SPY 2 trial, since 2010.
  • ), investigates the utility of a refined version of ImPrint, called ImPrintTN, designed to provide more accurate predictions to response to common immunotherapy (IO) regimens for TN patients.
  • “Many immunotherapy treatments can have difficult, severe adverse side effects on patients that can outweigh the benefit of the treatment.